var data={"title":"Technetium Tc-99m exametazime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m exametazime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/481090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-exametazime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m exametazime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452813\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ceretec;</li>\n      <li>Drax Exametazime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186280\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186423\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebral perfusion imaging (stroke):</b> IV (based on a 70 kg patient): 10 to 20 mCi (370 to 740 MBq); dynamic imaging may be performed between 0 to 10 minutes following injection; static imaging may be performed between 15 minutes to 6 hours after injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebral perfusion imaging (non-stroke) (off-</b>\n      <b>label uses):</b> IV: 15 to 30 mCi (555 to 1,110 MBq); images obtained after 40 minutes will be interpretable, however images obtained after 90 minutes will provide the best quality (ACR/SPR 2016; Juni 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leukocyte-labeled scintigraphy in intra-abdominal infection/inflammatory bowel disease:</b> IV: Tc 99m-labeled leukocytes: 7 to 25 mCi (259 to 925 MBq); optimal planar imaging is between 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leukocyte-labeled scintigraphy in non-abdominal infection/inflammation (off-label use):</b> IV: Tc 99m-labeled leukocytes: 5 to 10 mCi (185 to 370 MBq); obtain delayed imaging at 4 to 8 hours; if early images are negative, longer imaging time (16 to 24 hours) may be necessary (Palestro 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367906\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Risk for toxicities may be increased in patients with renal impairment; Tc 99m is substantially excreted by the kidney. There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, dose reduction may be considered if an adequate number of labeled white blood cells are administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367907\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452814\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit, Intravenous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ceretec: (5s) [vial contents to be combined with sodium pertechnetate Tc 99m injection solution (not included)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Drax Exametazime: (5s) [vial contents to be combined with sodium pertechnetate Tc 99m injection solution (not included)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452812\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20222939\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Follow manufacturer's labeling for administration. Instruct patient to void within 2 hours after administration to minimize radiation exposure (Juni 2009); patients should void frequently to minimize kidney and bladder exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Ensure adequate hydration before and after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186286\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Imaging agent:</b> Adjunct in detection of altered regional cerebral perfusion in stroke patients; leukocyte-labeled scintigraphy as an adjunct in localization of intra-abdominal infection and inflammatory bowel disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744926\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cerebral perfusion imaging (non-stroke); Non-abdominal infection sites (localization)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255273\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186438\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Facial edema, transient hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367899\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186336\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. Materials used in leukocyte preparation may also be associated with hypersensitivity; therefore, cells should be washed free of sedimentation agents prior to reinjection in the patient. Emergency resuscitation equipment and personnel should be immediately available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation accumulation: Tc 99m administration contributes to the patient&rsquo;s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Substantially excreted by the kidney; risk for toxicities may be increased in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Instruct patients to void when examination is completed, and frequently thereafter; encourage adequate hydration to facilitate frequent voiding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Risk for misinterpretation: Image interpretation errors may occur with Tc 99m exametazime; images may be affected by the presence of tumor, infarction, trauma, and other inflammatory conditions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186378\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186379\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Technetium Tc 99m exametazime crosses the placenta (Owunwanne, 1998); the amount of technetium Tc 99m that can be detected in fetal tissue depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein 1999; ICRP 2000; Parker 2004). Pregnancy status should be determined in women of childbearing potential (Parker 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13186398\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m is present in breast milk; excretion of exametazime is not known. The manufacturer recommends substitution with formula feeding for up to 60 hours (refer to manufacturer&rsquo;s labeling for product-specific recommendations) after administration of technetium Tc 99m exametazime to the mother.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In a case report, a nursing mother was administered technetium Tc 99m exametazime 500 mBq IV Peak activity in the breast milk was detected 6.5 hours after the injection and the calculated effective dose (0.26 mSv) was low enough that an interruption of breastfeeding would not have been necessary (Marshall 1996). When technetium Tc 99m exametazime is used to radiolabel autologous leukocytes, some sources recommended stopping breastfeeding for 12 to 48 hours (ICRP 2000; Stabin 2000; USNRC 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breastfeeding may be resumed (Harding 1995; Mountford 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994). Elective diagnostic procedures should be delayed until breastfeeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367909\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Monitor for hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367901\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22367902\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes to brain, muscle, and soft tissue </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Physical: ~6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~50%); Urine (~40%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777092\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Brain-Spect (CZ);</li>\n      <li>Cerestab (FR);</li>\n      <li>Ceretec (AT, AU, CY, CZ, DK, ES, FI, FR, GB, HU, IE, IL, IT, KR, LT, MT, NL, NO, PT, SE);</li>\n      <li>Leuco-Scint (CZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ. Administered radionuclides in pregnancy. <i>Teratology. </i>1999;59(4):236-239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR)/Society for Pediatric Radiology (SPR) Practice Parameter for the Performance of Single Photon Emission Computed Tomography (SPECT) Brain Perfusion Imaging, including Brain Death Examinations. 2016. Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/brainperf-spect.pdf?la=en. Accessed March 7, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceretec (technetium Tc exametazime) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics, Inc; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drax Exametazime (technetium Tc exametazime) [prescribing information]. Kirkland, Quebec, Canada: Jubilant DraxImage; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al. Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers. <i>Eur J Nucl Med.</i> 1995;22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP). Pregnancy and medical radiation. <i>Ann ICRP.</i> 2000;30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juni JE, Waxman AD, Devous MD Sr, et al, &quot;Procedure Guideline for Brain Perfusion SPECT Using (99m)Tc Radiopharmaceuticals 3.0,. J Nucl Med Technol. 2009;37(3):191-195. http://interactive.snm.org/docs/Brain_SPECT_Guideline_2003.pdf. Accessed August 26, 2011.19692453</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall DS, Newberry NR, Ryan PJ. Measurement of the Secretion of Technetium-99m Hexamethylpropylene Amine Oxime Into Breast Milk. <i>Eur J Nucl Med</i>.1996;23(12):1634-1635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/8929318/pubmed\" target=\"_blank\" id=\"8929318\">8929318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. <i>Nucl Med Commun.</i> 1989;10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Owunwanne A, Omu A, Patel M, et al. Placental Binding and Transfer of Radiopharmaceuticals: Technetium-99m d, 1-HMPAO. <i>J Nucl Med.</i> 1998;39(10):1810-1813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/9776293/pubmed\" target=\"_blank\" id=\"9776293\">9776293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palestro CJ, Brown ML, Forstrom LA, et al. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation. 2004. http://interactive.snm.org/docs/HMPAO_v3.pdf. Accessed March 7, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al. The excretion of radiopharmaceuticals in human breast milk: additional data and dosimetry. <i>Eur J Nucl Med.</i> 1994;21(2):144-153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. <i>J Nucl Med.</i> 2000;41(5):863-873.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/10809203/pubmed\" target=\"_blank\" id=\"10809203\">10809203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC). Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials. 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16805 Version 60.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452813\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13186280\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13186423\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22367906\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22367907\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20452814\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452812\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20222939\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13186286\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744926\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13255273\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13186438\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22367899\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13186336\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13186378\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13186379\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13186398\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22367909\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22367901\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F22367902\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777092\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16805|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-exametazime-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m exametazime: Patient drug information</a></li></ul></div></div>","javascript":null}